Jordan E. Axelrad MD, MPH, FACGAssociate Professor of Medicine; Director of Research, Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, New York
Jordan E. Axelrad, MD, MPH, is the Director of Research in the Inflammatory Bowel Disease Center at NYU Langone Health and an Associate Professor of Medicine in the Division of Gastroenterology, Department of Medicine, at NYU Grossman School of Medicine. Dr. Axelrad also directs the Clostridioides difficile and immunotherapy- related bowel diseases programs. He received his medical and public health degrees from Tufts University School of Medicine. He completed his internal medicine training at the Icahn School of Medicine at Mount Sinai and went on to complete fellowship training in gastroenterology at Columbia University Medical Center, serving as chief fellow. Dr. Axelrad received specialized training in clinical and translational inflammatory bowel disease investigation, and his research in areas such as environmental factors, and in malignant and infectious complications of inflammatory bowel disease, has been published and presented internationally. Dr. Axelrad is a member of multiple international gastrointestinal societies, is involved in inflammatory bowel disease guideline development and educational programs, and serves on the editorial board of multiple journals. He is the principal investigator of the institutional NYU inflammatory bowel disease biorepository, multiple clinical trials and international registries, and mentors trainees in various research activities. His current research is funded by the Crohn’s and Colitis Foundation, the Judith and Stewart Colton Center for Autoimmunity, the New York Crohn's and Colitis Organization, and the National Institutes of Health, and focuses on inflammatory bowel disease epidemiology, triggers of inflammatory bowel disease onset and flare, recurrent Clostridioides difficile, and models for predicting responsiveness to inflammatory bowel disease therapies.
Dr. Axelrad receives research grants from BioFire Diagnostics and Genentech; receives consultancy fees or honorarium from Abbvie, Adiso, BioFire Diagnostics, Bristol Myers Squibb, Janssen, and Pfizer.